Predictors of von Willebrand disease in children

Robert F Sidonio1, Sriya Gunawardena, Peter H Shaw

  • 1Division of Pediatric Hematology/Oncology, Department of Pediatrics, Monroe Carrell, Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee 37232-6310, USA. robert.f.sidonio@vanderbilt.edu

Pediatric Blood & Cancer
|January 13, 2012
PubMed

Insights

Assessing bleeding symptoms alone is not reliable for diagnosing von Willebrand disease (VWD) or low von Willebrand factor (VWF) in children. Further hemostatic testing is crucial for accurate diagnosis in pediatric patients.

Area of Science:

  • Pediatric Hematology
  • Hemostasis and Thrombosis

Background:

  • Bleeding and bruising are common reasons for pediatric hematology referrals.
  • Validated bleeding scores exist for adults but not definitively for children.
  • The study aimed to characterize pediatric bleeding symptoms and their predictive value for VWD or low VWF.

Purpose of the Study:

  • To describe presenting bleeding symptoms in pediatric patients.
  • To evaluate the predictive value of these symptoms for von Willebrand disease (VWD) or low von Willebrand factor (VWF).
  • To identify potential diagnostic markers for bleeding disorders in children.

Main Methods:

  • Retrospective chart review of 298 pediatric patients.
  • Standardized bleeding symptom inventory and hemostatic testing.
  • Logistic regression models used to assess predictors of VWD, low VWF, and platelet aggregation disorders.

Main Results:

  • 8% of patients had VWD, and 34% had low VWF.
  • 16% had nonspecific platelet aggregation disorders; 41% had normal hemostasis.
  • Neither personal/family bleeding history nor symptom count predicted VWD, low VWF, or platelet disorders.

Conclusions:

  • Qualitative assessment of bleeding symptoms alone is insufficient for diagnosing VWD or low VWF in children.
  • Hemostatic testing is essential for accurate diagnosis.
  • Current bleeding symptom assessments lack predictive power in this pediatric cohort.
Abstract

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pedigree Analysis01:35

Pedigree Analysis

Overview
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Probability Laws01:49

Probability Laws

Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...